about
Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary AdenomasLivin/BIRC7 expression as malignancy marker in adrenocortical tumors.Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study.Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome.PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer.Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer.Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany.Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas.Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors.ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas.Release and Decay Kinetics of Copeptin versus AVP in Response to Osmotic Alterations in Healthy Volunteers.Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma.Dosage-dependent regulation of VAV2 expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion.High resolution tissue mass spectrometry imaging reveals a refined functional anatomy of the human adult adrenal gland.Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma.Mitotane monotherapy in patients with advanced adrenocortical carcinoma.Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib.[Pheochromocytoma - Current Recommendations on Diagnostics, Therapy and Follow-up].Steroid Profiling for Adrenocortical Disorders: A Pathway for Omics-Based Diagnostics.Antwort.Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients.Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours.Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 PatientsComprehensive Characterization of Cancer Driver Genes and MutationsThe Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell CarcinomaEnzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patientsHsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotaneInfluence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis[Adrenal incidentaloma - what to do and what not?]A Copeptin-Based Approach in the Diagnosis of Diabetes InsipidusAdrenocortical incidentalomas and bone: from molecular insights to clinical perspectivesImpact of chronic hyponatremia on neurocognitive and neuromuscular function[Thyroid gland and the heart : Pathophysiological background, diagnostic and therapeutic consequences]Surviving ectopic Cushing's syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing's disease during long-term follow-upEffects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT StudyRole of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients
P50
Q33846427-D5C1E8C0-5A60-4C09-AF48-4F6882C5C14FQ36231629-F62EE841-0880-4D0E-992D-9C3469D59DA2Q37705961-B53BED6C-634F-439C-85AB-FA906E489E1BQ38640345-1DEA74DE-15C3-4433-A57E-15FEBFF36D49Q38752609-F2911B5E-50C7-4CA9-AFB1-4AB1C7D88517Q38759395-870AC99E-BBD1-4883-A931-8F557542576CQ38825846-98501384-BD42-42B4-B448-34EA75E47D6BQ38890111-9E53F76A-6216-4EA1-8758-2AA98F718FEFQ40282567-CEDB7788-9AAF-4CEE-BF1B-B04A241DBFDBQ40425821-2DFEC466-BF1E-46F0-B706-9E6EBB53F64AQ40437598-BF3D7277-7F6D-492D-A950-A2425CB35138Q42053452-7827BE7F-E0F5-4A79-97C6-D4BFED69C064Q47229083-65F5672C-63D7-43A7-A880-225DDCCBA9A6Q47350252-8F78CEEB-1710-468F-AA07-F1C4A992635CQ47671490-F00335B7-E861-42D2-86FD-18BB5B3A5DE8Q47801407-1D5D9116-A460-4907-8D02-0813E8DFD23AQ48153175-B4B989CB-8D06-4C94-92BF-DB46DDDD5121Q49552997-02D57840-630E-48E9-8BE1-F2C6BBFB6E36Q49568690-C2E84ACD-E7F7-48B5-B04A-DFA10A81FA09Q49922563-24C86A99-494E-4C1A-BFB9-59B116A50145Q50061666-A858C72D-D2B3-4857-BAB3-0D79661D00EBQ50064263-4A5B5D42-4315-4CBD-A0E1-1741BFAF0068Q50091291-142A8C17-EB40-4E22-9C65-4C01DAA12CC2Q50160388-D8CF30C0-49AE-4AF0-A5D3-E856CBF088CAQ51074593-D0C006EC-E0E0-4B32-81F3-F52BF583A2FCQ52714921-C82520F1-39A2-492A-876A-A71BA5C46836Q57261157-D66309D2-6EE9-4B70-9FD7-11558743A573Q57261160-59BE1855-1704-4F44-9834-3FD36AA20938Q57261171-245028DE-A225-401D-80F6-9D55A717B622Q57457125-1922891B-C316-4ADC-88C3-62CF40BAEDD6Q57478792-B737E800-C545-440B-AEF0-F5048A6B7561Q57486129-65ACA0FC-84D0-482A-B35E-284C83E0A020Q57641059-56366821-AEAD-49B0-8AE0-6F9B0E5CC52DQ60191439-1BBAFA38-42EF-4766-B647-0BDB074D0D48Q61958111-23D0DD43-82FA-4331-9F1F-293D693FED90Q62168806-5DDE5312-5620-4829-BDB8-18712BDCBED8Q88801480-1C4B7D82-9DE3-4D1A-A16B-FCB8A018484BQ89013810-46FBBEB3-82BA-476D-8DCA-AEFD4BEF1A22Q89597948-66D9FF41-95F9-4502-B9E7-BD4E035E182DQ90218053-EDB92786-AB4A-4DF9-8F26-D6FD6670618C
P50
description
researcher, ORCID id # 0000-0001-6170-6398
@en
wetenschapper
@nl
name
Martin Fassnacht
@ast
Martin Fassnacht
@en
Martin Fassnacht
@es
Martin Fassnacht
@nl
type
label
Martin Fassnacht
@ast
Martin Fassnacht
@en
Martin Fassnacht
@es
Martin Fassnacht
@nl
altLabel
Fassnacht M
@en
prefLabel
Martin Fassnacht
@ast
Martin Fassnacht
@en
Martin Fassnacht
@es
Martin Fassnacht
@nl
P106
P31
P496
0000-0001-6170-6398